|Mr. Jens H. Holstein||Chief Financial Officer and Member of Management Board||N/A||N/A||N/A|
|Dr. Marlies Sproll||Chief Scientific Officer (Leave of Absence) and Member of Management Board||N/A||N/A||59|
|Dr. Malte Peters||Chief Devel. Officer and Member of Management Board||N/A||N/A||55|
|Mr. Klaus De Wall||Head of Accounting & Tax||N/A||N/A||N/A|
|Mr. Sascha Allilovic||Head of Corp. Fin. and Corp. Devel.||N/A||N/A||N/A|
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase II clinical trials for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL-antibody directed against CD38, which is in Phase I/IIa trials for the treatment of multiple myeloma and various leukemias. The companys product pipeline also comprises MOR103, a human HuCAL-antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trials for treating rheumatoid arthritis; and MOR209/ES414, a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer that is in Phase I clinical trials for the treatment of metastatic castration-resistant prostate cancer. In addition, its product pipeline includes MOR106, a human monoclonal IL-17C antibody, which is in Phase I clinical trials for the treatment of atopic dermatitis; and MOR107, a novel lanthipeptide that is in Phase I clinical trials for the treatment of fibrotic diseases. The company was founded in 1992 and is headquartered in Planegg, Germany.
Morphosys AG’s ISS Governance QualityScore as of September 1, 2017 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 4.